Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS
- Resource Type
- Article
- Source
- In
Leukemia Research November 2021 110 - Subject
- Language
- ISSN
- 0145-2126